MicroRNA Market Size Worth $626.27 Million by 2025 | CAGR 18.6%

Grand View Research, Inc.

SAN FRANCISCO, June 18, 2018 /PRNewswire/ --

The global microRNA (abbreviated miRNA) market size is expected to reach USD 626.27 million by 2025, according to a new report by Grand View Research, Inc., posting a CAGR of 18.6% during the forecast period. A significant role of microRNAs in regulating gene expression. Their rapid adoption in development of diagnostic & prognostic tools for various cancer types is anticipated to provide a fillip to the market.

     (Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg )

Recent innovations in miRNA applications such as their use as potential biomarkers in advanced diagnostics have accelerated new product development. Based on existing technologies used in gene analysis such as microarrays, qRT-PCR, and sequencing, new products are being developed for better usage of miRNA. These are designed to overcome challenges faced when working with miRNA.

Investments in development of therapeutics & diagnostic tests based on miRNAs have increased tremendously over past few years. Regulus Therapeutics, Rosetta Genomics, Alnylam Pharmaceuticals, miRagen Therapeutics, and Mirna Therapeutics are some major companies involved in the development of RNA-based therapeutics. These players are involved in strategic partnerships to enhance their capabilities. For instance, in February 2018, STA Pharmaceutical Co., Ltd., a manufacturer of technology platform for small molecule pharmaceutical development signed an agreement with Regulus Therapeutics to provide its manufacturing facility to the company.

Academic & government research organizations are key revenue contributors as large number of microRNA research is carried out in these institutes. However, rising interest of biotech & pharmaceutical companies in miRNAs as biomarkers, especially in cancer screening, is providing a significant push to the market. MiRNA regulating gene expressions in Alzheimer's diseases, Autism Spectrum Disorders (ASD), Schizophrenia, and Parkinson's diseases have been identified. Soaring need for easy diagnosis of these diseases is projected to further increase demand for miRNA research tools.